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Abstract
Background: Mutations in Proline-rich Transmembrane Protein 2 (PRRT2) have been primarily associated with
individuals presenting with infantile epilepsy, including benign familial infantile epilepsy, benign infantile epilepsy,
and benign myoclonus of early infancy, and/or with dyskinetic paroxysms such as paroxysmal kinesigenic dyskinesia,
paroxysmal non-kinesigenic dyskinesia, and exercise-induced dyskinesia. However, the clinical manifestations of this
disorder vary widely. PRRT2 encodes a protein expressed in the central nervous system that is mainly localized in the
pre-synaptic neurons and is involved in the modulation of synaptic neurotransmitter release. The anomalous function
of this gene has been proposed to cause dysregulation of neuronal excitability and cerebral disorders.
Case presentation: We hereby report on a young child followed-up for three years who presents with a spectrum of
clinical manifestations such as congenital microcephaly, dysmorphic features, severe intellectual disability, and drug-
resistant epileptic encephalopathy in association with a synonymous variant in PRRT2 gene (c.501C > T; p.Thr167Ile) of
unknown clinical significance variant (VUS) revealed by diagnostic exome sequencing.
Conclusion: Several hypotheses have been advanced on the specific role that PRRT2 gene mutations play to
cause the clinical features of affected patients. To our knowledge, the severe phenotype seen in this case has
never been reported in association with any clinically actionable variant, as the missense substitution detected in
PRRT2 gene. Intriguingly, the same mutation was reported in the healthy father: the action of modifying factors in
the affected child may be hypothesized. The report of similar observations could extend the spectrum of clinical
manifestations linked to this mutation.
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Introduction
Reports on individuals with Proline-rich Transmem-
brane Protein 2 (PRRT2) mutations have varied greatly
in the clinical expressions, but most involve benign epi-
lepsies and/or dyskinetic paroxysms [1–7] which may
present in association [8] or within the same family [9].
At an early age, the PRRT2 mutations have been associ-
ated to benign familial infantile epilepsy, benign infantile
epilepsy, and benign myoclonus of early infancy [2, 4, 5].
The clinical features of infants with benign infantile epi-
lepsy are relativity typical, with seizures beginning in the
first days or months of life and tending to disappear very
early, usually within the first few years [10]. In these
infants, their developmental stages and physical examin-
ation are within the normal range. The PRRT2 muta-
tions have also been linked to paroxysmal dyskinesia, a
group of disorders in which the affected children show
episodic, sudden abnormal movements that are not asso-
ciated with loss of consciousness. These disorders in-
clude paroxysmal kinesigenic dyskinesia (PKD), triggered
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by voluntary or involuntary movements; paroxysmal
non-kinesigenic dyskinesia, which is not triggered by
voluntary movements; and paroxysmal exercise-induced
dyskinesia, triggered by repetitive motions and physical
exercise [2, 3, 6, 7]. The PRRT2 mutations have also
been reported in familial cases of hemiplegic migraine,
in children with benign paroxysmal torticollis, and in indi-
viduals with progressive and stable ataxia [1, 2, 11, 12].
Only rarely have been reported patients with PRRT2 mu-
tations presenting with severe neurological impairment
such as focal seizures and epileptic spasms [13], severe
epileptic seizures, cognitive disabilities, or complex mal-
formations [14–16]. However, the clinical manifestations
may vary widely as reported by Igarashi et al. [13] who de-
scribed a girl with Down syndrome (47, XY + 21) who ex-
hibited focal seizures and epileptic spasms during infancy.
Her younger brother had focal seizures at five months and
a normal development with normal interictal electro-
encephalogram. The father had infantile spasms and be-
nign PKD typical of PRRT2-related manifestations. In the
three patients, a mutation analysis of the PRRT2 gene dis-
closed a 841 T > C mutation. We report on a young child
with congenital microcephaly, facial dysmorphisms, and
severe epileptic encephalopathy. In this study, a compara-
tive genomic microarray analysis (aCGH) and a clinical
exome sequencing were carried out for the family trio
(both parents and their affected child sequenced simultan-
eously) to effectively detect de novo and compound het-
erozygous variants causing epileptic encephalopathy (EE),
motor and cognitive delay and seizure unresponsive to
treatment. Unsurprisingly, no rearrangements were found
in aCGH test and the gene panel sequencing identified
however, a heterozygous synonymous VUS in the gene
PRRT2 (c.501 C > T; p.Thr 167 =), inherited from the
healthy father.
Case report
The boy was first referred to our consultation at age of
2 months for a diagnostic work-up due to a neurological
assessment and epileptic seizures. The father is Italian,
and the mother is originally from Cuba but is now a
nationalized Italian citizen. The father was 31-years old
and the mother 27 at the time of gestation, during which
the mother felt fetal movements normally. The preg-
nancy was uneventful apart from some episodes of
vomiting happened in the first month of pregnancy. The
mother denied having had infectious disease or having
used drugs or alcohol during the pregnancy. At the fetal
age of 6 months, an intrauterine ultrasound disclosed a
head circumference in the lower range, but the parents
refused to interrupt the pregnancy. Just before the deliv-
ery, the mother was in a comatose state that lasted a few
hours, and a cesarean section was rapidly performed.
The child was born after 38 weeks’ gestation with a birth
weight of 2800 g, length of 48 cm, and head circumfer-
ence of 31 cm. The Apgar scores at 1 and 5min were 5
and 7, respectively. The child showed severe respiratory
distress at birth, and was immediately admitted to the
neonatal intensive care unit where he was endotracheally
intubated for 7 days. Facial dysmorphisms were noted
from the first hours of life and the child exhibited abnor-
mal clonic movements of the upper and lower limbs,
which were treated with intramuscular phenobarbital at
10 mg/kg/day with poor results. He was discharged from
the hospital 1 month after admission.
The boy first came to our observation at the age of
2 months with a weight of 3200 g, length of 53 cm, and
head circumference of 34 cm (< 3 SD). During the
hospitalization, the infant showed severe generalized
hypotonia and abnormal movements in clusters,
mainly of the migrant myoclonic type and localized to
the upper limbs. Episodes of horizontal gaze nystag-
mus were also noted. There was a lack of eye contact,
and the patellar reflexes were poorly elicited. At this
time, the EEG showed slow spikes in the right occipi-
tal region with dysregulated background activity, and a
brain ultrasound showed severe structural damage. An
electrocardiogram, thorax X-ray, and abdominal ultra-
sound were normal. Hemogram, electrolytes, urinaly-
sis, TORCH screen, and inflammatory marker test
gave normal results. Urinary organic acid and plasma
amino acid analyses were also normal. Deglutition was
impaired with severe dysphagia, and the deglutition
reflex was absent, requiring the infant be to fed by
nasogastric tube. The phenobarbital was increased to
7.5 mg twice a day, but the seizures persisted. At a
new admission at 3 months of age, the movements
were mainly dystonic and presenting during sleep.
Hypotonia was severe and generalized. A video-EEG
displayed multifocal, paroxysmal spike and wave activ-
ity that did not correlate with the dystonic movement
(Fig. 1). Adrenocorticotropic hormone (ACTH) treat-
ment was administered first for 2 weeks, and then with
valproate as an add-on, with poor response. The brain
MRI showed simplified cortical structures (shallow
sulci) with microcavitation localized primarily in the
pre- and post-rolandic subcortical white matter areas
(Fig. 2 a, b). Otoacoustic emission, impedentiometric,
and visual and auditory evoked potential analyses were
normal. In an attempt to reduce epileptic seizures
anticonvulsant treatment with levetiracetam, valpro-
ate, and topiramate, in isolation or in add-on, and a
ketogenic diet were carried out, but with poor results.
The child was followed-up over serial hospitalizations
every two to three months due to epileptic seizures of
various types, usually tonic rather than myoclonic, and
spasms in flexion with episodes of convulsive status
epilepticus. During the subsequent months, the child
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Fig. 1 Intercritical video-EEG performed at 3 months: showing slow spikes in the right occipital region with dys-regulated background
Fig. 2 a-b Brain MRI performed at 3 months: a T1 coronal sequence showing simplified cortical structures (shallow sulci); b T2 coronal sequence
showing micro cavitation localized in the pre and post rolandic subcortical white matter areas
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continued to show drug-resistant seizures, persistent
electroencephalographic abnormalities, and severe de-
velopmental delay.
At the physical examination performed at age 21
months, the child displayed a set of clinical signs con-
sisting of facial dysmorphic features, seizures, cognitive
disability, and severe language delay. The episodes of
epileptic seizures occurred frequently within short time
intervals and were drug resistant. The weight was 8.5 kg,
length 78 cm, and head circumference 43 cm (all below
the <3rd percentile). Facial dysmorphism consisted of a
small and receding forehead, sparse eyebrows, epi-
canthus, upslanting palpebral fissures, full cheeks, a wide
nasal bridge, rounded nasal tip, large nares, a long phyl-
trum, small mouth, thin lips, a horizontal furrow under
the lower lips, retrognathia, and a small nevus localized
on the upper lip (Fig. 3 a–b). The ears were large and
protruding with large lobules. The fingers were flexed
with the hands partially closed, and the thumbs were
long and adducted. The feet were long with a large big
toe. In a recent examination at the age of 3 years, the
weight was 11.2 kg (3rd percentile), length 85 cm (3rd
percentile), and head circumference 43 cm (<3rd per-
centile) (Fig. 4) The child continued to show develop-
mental delay and drug-resistant epileptic seizures.
Moreover he presented daily febrile temperature ranging
from 40 °C to 37 °C, without response to antipyretic
drugs and without a clear infectious cause and without
sweating. Nowaday, under anticonvulsivant treatment,
the child showed a reduction of seizures, which appeared
prevalently at awake and a series of two or three epi-
sodes at day. The daily thermal variation without a
known cause led us to suppose as co-morbility, a ther-
mal dysregulation of hypothalamic origin suggestive of
reverse Shapiro’s syndrome. The MRI at the age of 3
years showed a moderate enlargement of both lateral
ventricles and subarachnoid space of bilateral temporal
pole with volume reduction of the supratentorial white
matter (Fig. 5 a-b).
During the frequent admissions to the hospital, several
specific analyses have been performed with the aim of
defining the etiological event with the following results
(normal values in parentheses): neopterin, 1.16 μg/L
(2.30–10.10); biopterin, 2.88 μg/L (2.40–11.80); neu-
rotransmitters 5-hydroxyindole acetic acid (5HIAA),
330 nmol/L (152–462); homovanillic acid (HVA),
268 nmol/L (302–845); 3–0-methyldopa, 36 nmol/L
(< 100); 5-hydroxytryptophan (5-HTP), 7 nmol/L (>
10); 3-methoxy-4-hydroxyphenylglycol, 7 nmol/L (51–
112); HVA/5HIAA 0.81 (1.50–3.50).
Genetic testing
Genomic DNA isolation was carried out for the family
trio (father, mother and child affected). Array Compara-
tive Genome Hybridization (aCGH) was performed by
CytoSure ISCA 8x60k array from Oxford Gene Technol-
ogy (OGT), according to the manufacturer’s recommen-
dations (Agilent Technologies, Santa Clara, CA). aCGH
data were analyzed and interpreted using Cytosure soft-
ware (GRCh38 assembly) provided by OGT. In addition
to this, a targeting enrichment was performed using the
Illumina TruSight One panel, a diagnostic panel of 47
EE genes containing probes to capture the exonic re-
gions of 4813 genes associated with the clinical pheno-
type. The samples were sequenced by using the Illumina
NextSeq 500 platform (Illumina Inc.) with 2 × 150 bp
paired-end reads. Alignments and variant calls were gen-
erated using NextGene software (v2.4.1, 2015) and vari-
ant calls (with coverage <15X) were limited to the genes
of interest. For the clinical interpretation of genomic
variants was used Alamut-Batch (Version 1.4.0, 2015),
the high-throughput annotation software for NGS ana-
lysis. Variants were annotated for minor allele frequencies
in the Exome Aggregation Consortium (ExAC) database
Fig. 3 a-b. At the age of two-and-a-half years, the child notes: a a small and receding forehead, sparse eyebrows, epicanthus, upslanting
palpebral fissures, full cheeks, a wide nasal bridge, rounded nasal tip, large nares, b The wrist and fingers were flexed with the hands
partially closed
Pavone et al. Italian Journal of Pediatrics          (2019) 45:159 Page 4 of 9
(Version 0.3), and heterozygous variants with minor allele
frequencies > 0.01 (1%) were filtered out. Variants were
classified as pathogenic/likely pathogenic/VOUS/likely be-
nign/benign according to the 2015 American College of
Medical Genetics and Genomics (ACMG) guidelines [17].
Alamut Visual (Version 2.7) was used for integrating gen-
etic and predictive information on missense, nonsense,
frameshift, and splice-site variants, providing computa-
tional algorithms for SIFT and PolyPhen-2 (Version 2.2.2,
2012). The validation of variants classified as pathogenic
or likely pathogenic was performed using Sanger sequen-
cing in the proband.
Results
Molecular karyotype analysis did not show any copy
number alterations. Using a targeted epileptic encephal-
opathy (EE) panel, we identified a heterozygous variant
of uncertain significance (VUS) in the gene PRRT2
(Fig. 6). The variant results in a synonymous amino acid
substitution (c.501 C > T; p.Thr 167 =) and was detected
Fig. 4 At 3 years, to note: long philtrum, small mouth, thin lips and a horizontal furrow under the lower lips, retrognathia and a small nevus
localized on the upper lip
Fig. 5 a-b: Brain MRI performed at 3 years: a) Axial T1-weighted image and b) Axial T2-weighted image: moderate enlargement of both lateral
ventricles and subarachnoid space of bilateral temporal pole with volume reduction of the supratentorial white matter
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in the unaffected father, but not reported in the mother.
The variant c.501 > C > T is likely benign (2015 ACMG
classification) but, it is not observed in large population
cohorts (gnomAD).
Discussion
The boy presents with facial dysmorphism, congenital
microcephaly, severe developmental delay, and drug-
resistant epileptic encephalopathy. The main dysmorphic
features consist of a small receding forehead, epicanthus,
upslanting palpebral fissures, a large nasal bridge with a
rounded tip, a long philtrum, small mouth, thin lips,
horizontal furrow under the lower lip, and retrognathia.
He was markedly hypotonic with severe cognitive dis-
ability. The epileptic seizures were initially of the early
myoclonic type that subsequently transitioned to spasms
in flexion associated with episodes of convulsive status
epilepticus that required frequent admission to the in-
tensive therapy unit. Serial EEG persisted in showing
multifocal paroxysmal spike and wave activity. Brain
MRI showed simplified cortical sulci and microcavita-
tions, the latter possibly related to the severe hypoxic-
ischemic encephalopathy (HIE) of perinatal origin. How-
ever, in this child the microcephaly was not linked to the
HIE as it was prenatally recognized by uterine ultra-
sound and confirmed at birth by head circumference
measurement less than the third percentile. In contrast
to what has been observed with the present child, usu-
ally infants with HIE have a head circumference meas-
urement within the normal range at birth. As reported
in a study on 52 term infants, no statistical difference
was noted between the head circumference of newborns
with HIE and normal control infants [18]. The clinical
manifestations of HIE have certainly played a role in the
neurologic involvement of this child, but it must be con-
sidered a co-morbid event. The complex clinical features
presented by the child, particularly the signs of severe
epileptic encephalopathies led us to carry out a panel of
molecular analyses related to these disorders, but the
genes examined were not informative.
A diagnostic exome sequencing analysis of the pro-
band detected a variant of uncertain significance for the
PRRT2 gene, which could have played a role in the
clinical manifestations presented by the child. PRRT2
Fig. 6 Schematic representation from NCBI Sequence Viewer 3.32.0 of the VUS detected by exome sequencing. The upper panel corresponds to
the screenshot from NCBI Sequence Viewer showing the missense sequence variant c.501 C > T in the exon 2 of the PRRT2 gene. The red line
indicates the VUS position around which a range of clinical variants annotated in dbSNP flanking the site of mutation, thereby giving evidence of
a region susceptible to gene expression variability. In the lower panel, on the left the red circle highlights the codon of interest, and on the right,
it was shown the consensus coding sequence (CCDS) and the corresponding substitution of threonine 167 where occurs the mutated base
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encodes a protein expressed in the central nervous sys-
tem that is mainly localized in the pre-synaptic neurons
and involved in the modulation of synaptic neurotrans-
mitter release. A reduction or no production of the
PRRT2 protein might cause alterations in synaptic
neurotransmitter release and/or a dysregulation of the
neuronal excitability in different sides of the brain, caus-
ing different types of neurological disorders [2, 19–22].
The PRRT2 mutation has been predominantly related to
individuals and families with a wide group of early onset
paroxysmal disorders such as PKD and different types of
benign infantile seizures [2, 4, 5]. A study on the inci-
dence of PRRT2 mutations in a cohort of 16 PKD
patients and their relatives (a total of 39 individuals) was
conducted by Lamperti et al. [3] that found PRRT2
mutations in 10 of the 16 patients and in 23 relatives. In
27 of the 33 individuals the mutations was c.insC649
p.Arg217Profs*8. For this group of patients, the mean
age of onset was 10 years, and the PKD episodes were
generalized and ranged from a few minutes to several
days. No associations with epileptic seizures or EEG
abnormalities were reported. In another study of 11 pa-
tients with paroxysmal hypnogenic dyskinesia, mutations
in the PRRT2 gene were found in two typical patients
[23]. In a cohort of Chinese families with members
affected by paroxysmal kinesigenic dyskinesia, infantile
convulsions, and choreoathetosis, direct sequencing
showed three different pathogenic mutations (c.649dupC,
c.776dupG, and c.649C→T) in the PRRT2 gene [24].
These authors found no clear evidence of a genotype-
phenotype correlation regarding the age of onset or the
types of mutations [24]. Ebrahimi-Fakhari et al. [2] per-
formed a wide review of 1444 published cases of PRRT2
mutations using a systematic approach to the clinical and
genetic characteristics of this group of patients. A positive
family history was reported in 89.1% of the patients, and
in 87.1% of the reported cases, the PRRT2 mutations were
familial in origin. In this study, benign familial infantile
epilepsy was found in 602 infants (41.7%), paroxysmal
kinesigenic dyskinesia in 560 (38.7%), and infantile convul-
sions and choreoathetosis in 206 (14.3%). Only 76 patients
(i.e., 5.3%) presented with a primary diagnosis unrelated to
these disorders.
As previously mentioned, the clinical spectrum of indi-
viduals affected by PRRT2 gene mutations is wide, and it
is difficult to correlate genotype with phenotype. The
two more frequent clinical expressions of PRRT2 muta-
tions causing benign infantile epilepsies and paroxysmal
dyskinesia tend to manifest with such different clinical
expressions and ages of onset that it is difficult to
provide a single etiological explanation for so different
clinical manifestations [24]. The proband in our study
presents unusual clinical features compared with those
reported for other individuals affected with PRRT2
mutations, and congenital microcephaly, severe brain in-
volvement, and dysmorphisms have not been previously
reported in patients with this mutation. PRRT2 muta-
tions were found in only a few cases when 70 genes were
genetically tested in 8565 patients with epilepsy and
neurodevelopmental disorders [16]. A report by Trump
et al. [20] on a cohort of 400 patients with early onset
epilepsy and severe developmental delay disorders found
PRRT2 mutations in only two patients. Delcourt et al.
[14] support the hypothesis that homozygous or com-
pound heterozygous deleterious PRRT2 gene mutations
may present with more severe clinical expression com-
pared to those resulting from a single mutation [14]. In
a study of 5 patients [14], the authors report complex
phenotypes consisting of (1) a combination of at least
three different forms of paroxysmal neurological disor-
ders within the same patient and persistent paroxysmal
attacks; (2) prolonged episodes of ataxia; and (3) associ-
ated neurologic disorders that include learning difficul-
ties in four patients and cerebellar atrophy in two
patients. Liu et al. [15] hypothesize that knocked down
PRRT2 expression in vivo might result in embryonic
delay in neuronal migration with a marked reduction in
synaptic density after birth.
We dealt with a complex clinical case for data inter-
pretation. Gene panel sequencing failed to identify
causal variants possibly correlated with the clinical signs
presented by the child. The analysis did not show the
presence of point mutations in the translated regions or
in the intron-exon junctions of the examined EE genes.
The missense variant in PRRT2 gene (c.501C > T;
p.Thr167Ile) reported in the proband and in the healthy
father has not been associated as pathogenetic neither in
the ClinVar database and Single Nucleotide Polymorph-
ism Database (dbSNP) (Fig. 6, upper panel). Actually,
this result does not exclude that the protein structural
change has not proven sufficiently robust to be clinically
useful.
Although the neutral mutation may have a minimal
impact in the gene product, synonymous does not mean
the same, therefore, an identical variation may impair
the gene regulation and affect the site of conserved se-
quence motifs of transcription factors [25, 26]. It could
not be excluded to also influence aberrant mRNA spli-
cing and specific DNA methylation signatures [27–29].
In attempt to evaluate the genomic context in which
the VUS is included, we performed a predictive analysis
for the identification of putative transcription factor
binding sites (TFBS) in DNA sequence with the PROMO
website tool (http://alggen.lsi.upc.es/cgi-bin/promo_v3/
promo/promoinit.cgi?dirDB=TF_8.3), using data from
TRANSFAC database version 8.3 [30, 31]. The PROMO
output (Fig. 7) showed that the genomic position of VUS
is enriched for 14 transcription factors (XPF-1, ABI4,
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CAC-binding protein, ADR1, VDR, ZIC1, ZIC2, ZIC3,
TFIIB, MIG1, SP3, NF-E4, VPR and USF-1).
However, this report does not exclude that further
studies on the conservation of the amino acid involved
and conformational regulation in the downstream signaling
protein interactions will be needed to investigate new in-
sights into the pathogenicity of the non-synonymous substi-
tutions. Intriguingly, according to all mutations reported to
date, the exon 2 encoding the extracellular and the proline-
rich domain of the protein is prevalently associated with a
wide number of missense variants, some of those likely
pathogenic, but the majority are likely benign, with inter-
mediate predictions and without a specific disease setting
[32]. Given the normal phenotype of the proband’s father,
the role of the missense substitution may also underlie the
complexity of a genetic-phenotype correlation and suggest
the incomplete penetrance frequently encountered in dom-
inantly inherited epilepsies. Furthermore, it may be hypoth-
esized that in the affected child modifying factors may have
acted in causing the severe clinical features. Genetic hetero-
geneity, the involvement of other genes or the non-coding
regions of the PRRT2 gene, as well as epigenetic effects may
have acted during fetal development to provoke in the child
severe clinical expressions.
In conclusion, the severe clinical features presented by
the child in association with the missense variant of
PRRT2 might extend the spectrum of clinical manifesta-
tions [24]. We provided points to consider stimulating
this debate across other similar observations, which
could help to clarify the clinical interpretation of the
VUS and other factors influencing the clinical expression
of such a severe disorder [24, 33, 34].
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